{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:28:59Z","timestamp":1790908139829,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,4,28]],"date-time":"2005-04-28T00:00:00Z","timestamp":1114646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In 1986, a Phase II trial of recombinant interferon\u2010\u03b1 (IFN\u2010\u03b1) was initiated as therapy for patients with essential thrombocythemia (ET).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients were treated with subcutaneous IFN\u2010\u03b1 at a dose of 5 \u00d7 10<jats:sup>6<\/jats:sup> units\/m<jats:sup>2<\/jats:sup> daily. In responding patients, the therapy lasted at least 3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010three patients (14 females and 9 males; median age, 41 years; age range, 20\u201363 years) with a median platelet count of 1350 \u00d7 10<jats:sup>9<\/jats:sup>\/L were treated. After a median follow\u2010up of 174 months (14.5 years), 15 of 20 evaluable patients (75%) responded, including 14 patients who achieved a complete hematologic response (CHR) (6 of them with bone marrow remission) and 1 patient who demonstrated a partial response. The median time to response was 6 months (range, 0.5\u201336 months), and the median response duration was 48 months (range, 5\u2013114 months). Seven patients who achieved a CHR and were taken off therapy after they completed 3 years of maintenance therapy sustained their response for a median of 28 months. No symptoms or signs of thrombosis or hemorrhage were observed in responding patients. Eleven of 14 patients (78%) who achieved a CHR developed a recurrence, and 2 of 5 patients with recurrences who were rechallenged with IFN\u2010\u03b1 achieved a second response. The treatment was tolerated relatively well.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>IFN\u2010\u03b1 was safe and effective therapy for patients with ET, and the ability of IFN\u2010\u03b1 to reverse disease pathology and possibly modify the clinical course of patients with ET warrants its investigation in larger, prospective trials. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21086","type":"journal-article","created":{"date-parts":[[2005,4,28]],"date-time":"2005-04-28T12:47:19Z","timestamp":1114692439000},"page":"2551-2557","source":"Crossref","is-referenced-by-count":20,"title":["Interferon \u03b1 therapy for patients with essential thrombocythemia"],"prefix":"10.1002","volume":"103","author":[{"given":"Rashid","family":"Saba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil J.","family":"Freireich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1188","volume-title":"Hematology: basic principles and practice","author":"Hoffman R","year":"2000"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V15.5.706.706"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1977.tb00996.x"},{"key":"e_1_2_6_5_2","first-page":"165","article-title":"Essential thrombocythemia: clinical and laboratory characteristics at presentation","volume":"96","author":"Iland HJ","year":"1983","journal-title":"Trans Assoc Am Physicians."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92021-9"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04408.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea; high proportion of cases with 17p deletion","volume":"91","author":"Sterkers Y","year":"1998","journal-title":"Blood."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198611000-00001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00026-2"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/1024533021000047990"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074373"},{"key":"e_1_2_6_13_2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830300112"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1602"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996112"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.4.863"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"5a","DOI":"10.1182\/blood.V104.11.6.6","article-title":"The Medical Research Council PT1 trial in essential thrombocythemia","volume":"104","author":"Green A","year":"2004","journal-title":"Blood."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02584.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3083125.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon\u2010alpha directly represses megakaryopoiesis by inhibiting thrombopoeitin\u2010induced signaling through induction of SOCS\u20101","volume":"96","author":"Wang Q","year":"2000","journal-title":"Blood."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.4.1173.1173"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90005-0"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074371"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(97)90001-1"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059658"},{"key":"e_1_2_6_29_2","first-page":"277","article-title":"Recombinant alpha 2a interferon (alpha IFN) in the treatment of essential thrombocythemia: preliminary report","volume":"72","author":"Gugliotta L","year":"1987","journal-title":"Haematologica."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909145955"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602317314064"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01738297"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400931"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400885"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0533-4"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21086","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:03:54Z","timestamp":1760277834000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21086"}},"subtitle":["Final results of a phase II study initiated in 1986"],"short-title":[],"issued":{"date-parts":[[2005,6,2]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,6,15]]}},"alternative-id":["10.1002\/cncr.21086"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21086","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,2]]}}}